# TIL Cells for the Treatment of the Advanced Solid Tumors Patients

> **NCT05649618** · EARLY_PHASE1 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** Tumor Infiltrating Lymphocytes
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide Capsules
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT05649618
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-05
- **Primary completion:** 2024-03
- **Final completion:** 2026-03
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05649618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05649618, "TIL Cells for the Treatment of the Advanced Solid Tumors Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05649618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*